Pharmacogenomics: Future promise of a tool for identifying patients at risk

Drug Information Journal

Volumn 34, Issue 1, 2000, Pages 223-227

  Kurth, Janice H ^a  

^a Phenogenex   (United States)

Author keywords

Adverse events; Drug safety; Patient risk; Pharmacogenetics; Pharmacogenomics

Indexed keywords

DEXFENFLURAMINE; FELBAMATE; TERFENADINE; TROGLITAZONE;

ARTICLE; DRUG METABOLISM; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; MEDICAL DECISION MAKING; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT PLANNING;

EID: 0034116866     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150003400130     Document Type: Article

References (4)

1. Weber WW. Pharmacogenetics. New York, NY: Oxford University Press; 1997.
2. th ed. New York, NY: McGraw-Hill, Inc.; 1996:113-186.
3. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998; 70(5):1781-1792.
4. Poirier J. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Psychiatry Neurosci. 1999;24(2):147-153.